TAIJI GROUP(SH:600129) Ge Long Hui·2025-09-29 03:48Core Insights - Tai Chi Group's subsidiary Southwest Pharmaceutical has had its application for the generic version of Atomoxetine Hydrochloride Capsules accepted, with the original product set to cease supply in the Chinese market by January 2024 [1][2] - Atomoxetine, originally developed by Eli Lilly, is a non-stimulant medication recommended for treating ADHD in children and adolescents, with significant sales growth in the Chinese market [2][4] Company Developments - Southwest Pharmaceutical is currently the only company actively pursuing a 4th category new registration for the generic version of Atomoxetine Hydrochloride Capsules [4] - The company has increased its investment in the neuropsychiatric drug sector, with total R&D expenditure rising from 14.6 million to 28.2 million yuan from 2021 to 2024, representing an increase in revenue proportion from 1.20% to 2.28% [13][15] Market Context - The total sales of neuropsychiatric drugs in the hospital market are projected to exceed 110 billion yuan in 2024, with major market players including Renfu (21.31% market share), Shiyao Group (16.8%), and Yangtze River Pharmaceutical (approximately 13%) [4] - In 2021, the sales of Atomoxetine Hydrochloride Capsules in the full-terminal hospital market surpassed 300 million yuan, reflecting a year-on-year growth rate of 46.64% [2][4]